loading
Zyversa Therapeutics Inc stock is traded at $0.70, with a volume of 432.74K. It is up +7.53% in the last 24 hours and up +6.66% over the past month. ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
See More
Previous Close:
$0.651
Open:
$0.65
24h Volume:
432.74K
Relative Volume:
0.13
Market Cap:
$3.34M
Revenue:
-
Net Income/Loss:
$-21.33M
P/E Ratio:
-0.00615
EPS:
-113.7479
Net Cash Flow:
$-9.12M
1W Performance:
-1.41%
1M Performance:
+6.66%
6M Performance:
-35.78%
1Y Performance:
-80.17%
1-Day Range:
Value
$0.65
$0.7098
1-Week Range:
Value
$0.631
$0.73
52-Week Range:
Value
$0.4728
$6.30

Zyversa Therapeutics Inc Stock (ZVSA) Company Profile

Name
Name
Zyversa Therapeutics Inc
Name
Phone
908-370-5102
Name
Address
217 W. MAIN STREET, SOMERVILLE
Name
Employee
7
Name
Twitter
Name
Next Earnings Date
2024-08-19
Name
Latest SEC Filings
Name
ZVSA's Discussions on Twitter

Compare ZVSA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ZVSA
Zyversa Therapeutics Inc
0.70 3.34M 0 -21.33M -9.12M -113.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Zyversa Therapeutics Inc Stock (ZVSA) Latest News

pulisher
Jun 16, 2025

Critical Analysis: ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Schrödinger (NASDAQ:SDGR) - Defense World

Jun 16, 2025
pulisher
Jun 14, 2025

ZyVersa Therapeutics (NASDAQ:ZVSA) Upgraded at Wall Street Zen - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

ZyVersa Therapeutics Stockholders Approve Key Proposals - TipRanks

Jun 12, 2025
pulisher
Jun 11, 2025

Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World

Jun 11, 2025
pulisher
Jun 06, 2025

At $0.65 Price, ZyVersa Therapeutics Inc (ZVSA) Is Sitting And Waiting - Stocksregister

Jun 06, 2025
pulisher
Jun 05, 2025

ZyVersa Therapeutics Reports Q1 2025 Financial Results - TipRanks

Jun 05, 2025
pulisher
May 31, 2025

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Sees Large Drop in Short Interest - Defense World

May 31, 2025
pulisher
May 20, 2025

ZVSA: ZyVersa Therapeutics' IC 100 Shows Promise in PD Treatment - GuruFocus

May 20, 2025
pulisher
May 20, 2025

ZyVersa’s IC 100 shows promise in Parkinson’s treatment By Investing.com - Investing.com India

May 20, 2025
pulisher
May 20, 2025

ZyVersa Therapeutics highlights publication of data on IC 100 - TipRanks

May 20, 2025
pulisher
May 20, 2025

ZyVersa’s IC 100 shows promise in Parkinson’s treatment - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

ZyVersa Therapeutics Highlights Published Study Reinforcing - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough Study Reveals Key to Fighting Parkinson's: ZyVersa's Novel Drug Shows Promise in $13B Market - Stock Titan

May 20, 2025
pulisher
May 12, 2025

ZyVersa Therapeutics, Inc. Provides Pipeline and Financial Update: Advances in Clinical Trials for VAR 200 and IC 100 - Nasdaq

May 12, 2025
pulisher
May 12, 2025

ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress - GlobeNewswire

May 12, 2025
pulisher
May 09, 2025

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps - MSN

May 09, 2025
pulisher
May 08, 2025

Retail Traders Flock To ZyVersa As IC 100 Obesity Plan Looks To Fill GLP-1 Gaps By Stocktwits - Investing.com India

May 08, 2025
pulisher
May 07, 2025

ZyVersa Unveils Groundbreaking Potential of Inflammasome - GlobeNewswire

May 07, 2025
pulisher
May 07, 2025

ZyVersa Therapeutics announces developments on inflammasome inhibitors - TipRanks

May 07, 2025
pulisher
May 07, 2025

ZyVersa progresses with obesity inflammation treatment - Investing.com Australia

May 07, 2025
pulisher
May 07, 2025

ZyVersa Unveils Potential Of Inflammasome Inhibitors In Combination With GLP-1 Agonists To Address Needs Of People Living With Obesity - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update - Stock Titan

May 07, 2025
pulisher
Apr 30, 2025

ZyVersa Therapeutics Inc [ZVSA] is -36.75% lower this YTD. Is it still time to buy? - dbtnews.com

Apr 30, 2025
pulisher
Apr 29, 2025

ZyVersa Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

How does ZVSA’s price to cash per share ratio compare in the market? - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

Study finds inflammation-targeting drug has Parkinson’s potential - Longevity.Technology

Apr 29, 2025
pulisher
Apr 29, 2025

ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

Zyversa Therapeutics Announces Published Data Showing Inflammasome Asc Inhibitor IC 100 Decreases Microglial Inflammasome Activation - marketscreener.com

Apr 29, 2025
pulisher
Apr 29, 2025

ZVSA: ZyVersa Therapeutics Unveils Promising Data on Parkinson's Treatment | ZVSA Stock News - GuruFocus

Apr 29, 2025
pulisher
Apr 29, 2025

ZyVersa Therapeutics Announces Promising Data for Inflammasome ASC Inhibitor IC 100 in Parkinson's Disease Research - Nasdaq

Apr 29, 2025
pulisher
Apr 29, 2025

ZyVersa Therapeutics Announces Published Data Showing - GlobeNewswire

Apr 29, 2025
pulisher
Apr 29, 2025

Game-Changing Parkinson's Treatment: Nature Study Reveals Drug's Dual-Action Against Disease Progression - Stock Titan

Apr 29, 2025
pulisher
Apr 24, 2025

ZyVersa progresses with novel inflammation treatment By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

ZyVersa progresses with novel inflammation treatment - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

ZyVersa's IC 100 Drug Targets $186B Market, Sets 2025 Clinical Timeline | ZVSA Stock News - Stock Titan

Apr 24, 2025
pulisher
Apr 22, 2025

ZyVersa Therapeutics files to sell 4.21M shares of common stock by selling shareholders - MSN

Apr 22, 2025
pulisher
Apr 10, 2025

Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

10 Stocks Fall Behind Amid Market Optimism - Insider Monkey

Apr 10, 2025
pulisher
Apr 09, 2025

ZyVersa CEO outlines progress in kidney disease drug development - Investing.com

Apr 09, 2025
pulisher
Apr 09, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Apr 09, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa CEO outlines progress in kidney disease drug development By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Highlights Potential of IC 100 for O - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Reports 2024 Financial Results and P - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics (ZVSA) Secures $2 Million Through Securitie - GuruFocus

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa CEO issues shareholder letter on PARASOL recommendations - TipRanks

Apr 08, 2025
pulisher
Apr 08, 2025

ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) - GlobeNewswire

Apr 08, 2025
pulisher
Apr 07, 2025

ZyVersa Therapeutics appoints new accounting firm - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

ZyVersa Therapeutics appoints new accounting firm By Investing.com - Investing.com India

Apr 07, 2025

Zyversa Therapeutics Inc Stock (ZVSA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Cap:     |  Volume (24h):